Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | FASN | P49327 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 5/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 5/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 5/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.33 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 2/20 | 0.32 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.32 |
| ▸ | CSF1R | P07333 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24927200 | 0.99 | MEN1 (0.34) | MEN1KMT2AFASNGABRA1GABRG2 | |
| SCHEMBL24926781 | 0.98 | MEN1 (0.36) | MEN1KMT2AFASNGABRA1GABRG2 | |
| SCHEMBL24927221 | 0.97 | MEN1 (0.33) | MEN1KMT2AFASNGABRA1GABRG2 | |
| SCHEMBL24926922 | 0.96 | MEN1 (0.34) | MEN1KMT2AFASNGABRA1GABRG2 | |
| SCHEMBL24927658 | 0.96 | MEN1 (0.37) | MEN1KMT2AFASNENPP3DPP4 | |
| SCHEMBL24926768 | 0.95 | MEN1 (0.33) | MEN1KMT2AFASNGABRA1GABRG2 | |
| SCHEMBL24927156 | 0.94 | MEN1 (0.37) | MEN1KMT2AFASNENPP3DPP4 | |
| SCHEMBL24927456 | 0.93 | MEN1 (0.39) | MEN1KMT2AFASNDPP4SSTR2 | |
| SCHEMBL24927241 | 0.93 | GABRG2 (0.34) | GABRA1GABRG2GABRB3GABRA2GABRA5 | |
| SCHEMBL24927177 | 0.92 | MEN1 (0.34) | MEN1KMT2AFASNENPP3DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230301179-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-09-21 | — | — | US | disclosed |
| US-20230301179-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-09-21 | — | — | US | disclosed |
| US-20230174560-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-06-08 | — | — | US | disclosed |
| US-20230174560-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-06-08 | — | — | US | disclosed |
| US-20230165130-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE HETEROCYCLIC COMPOUND, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-05-25 | — | — | US | disclosed |
| US-20230165130-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE HETEROCYCLIC COMPOUND, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-05-25 | — | — | US | disclosed |
| US-20230034532-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2023-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165130-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE HETEROCYCLIC COMPOUND, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | CYP1A1, CYP2E1, AOX1 | MEN1 334/4885KMT2A 1066/4885FASN 3893/4885 |
| US-20230174560-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | CRY1, AOX1, CYP1A1 | MEN1 318/4885KMT2A 1345/4885FASN 3821/4885 |
| US-20230034532-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | NR0B1, CRY1, CCNT1 | MEN1 404/4885KMT2A 3254/4885FASN 4199/4885 |
| US-20230301179-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | CRY1, AOX1, CYP1A1 | MEN1 367/4885KMT2A 1497/4885FASN 3600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.